Myriad Genetics Q4 EPS Beats by $0.06, Adjusted EBITDA Doubles Estimates
Myriad Genetics posted Q4 revenue of $209.8 million, slightly above forecasts, delivered $0.04 adjusted EPS versus an expected $0.02 loss, and achieved $14.3 million in adjusted EBITDA, more than doubling estimates. Full-year EBITDA guidance rose to $43 million, boosting shares 4.9% intraday to $4.55 after a 22% rally, despite flat year-over-year revenue.
1. Q4 Earnings Beat
Myriad Genetics reported Q4 revenue of $209.8 million, slightly ahead of consensus estimates, and delivered adjusted EPS of $0.04 versus a projected $0.02 loss.
2. Profit and Guidance
Adjusted EBITDA reached $14.3 million, more than doubling expectations, while management raised full-year EBITDA guidance to $43 million.
3. Stock Reaction
Shares surged 4.9% intraday to $4.55 following the results and guidance boost, building on a 22% jump in the previous session, despite flat year-over-year revenue.
4. Valuation Context
At $4.55, shares trade 67% below the 52-week high of $13.78, reflecting longer-term investor skepticism.